Increased Thioredoxin-1 Expression Promotes Cancer Progression and Predicts Poor Prognosis in Patients with Gastric Cancer

Figure 1

Trx-1 upregulation is associated with poor prognosis in GC. (a) Using the GSE13911 data set, differences in the Trx-1 mRNA expression levels were explored between the GC and normal tissues. (b) In the GSE15460 cohort, the patients were dichotomized into subgroups with high or low Trx-1 mRNA expression according to the Trx-1 expression level cutoff value across the cohort. The Kaplan-Meier curves were compared using the log-rank test. The median survival time was 34 months for the high Trx-1 expression group and >150 months for the low Trx-1 expression group. (c) Representative immunostaining of Trx-1 in gastric cancer tissues. Bar, 100 μm. (d) Significant upregulation of Trx-1 protein expression was observed in GC with lymph node metastases relative to GC without lymph node metastasis. (e) Kaplan-Meier curves for GC patients demonstrating that those with high Trx-1 expression had a shorter survival time compared with low Trx-1-expression. The median survival time was 31 months for the high Trx-1 expression group and >100 months for the low Trx-1 expression group. GC: gastric cancer. value is presented in the figures.

(a)

(b)

(c)

(d)

(e)